




		EMLc	ATC codes: <a href="#">L01DB02</a>
Indication	Lymphoid leukaemia, not elsewhere classified	ICD11 code: <a href="#">2C03.3</a>	
INN	Daunorubicin		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection ; 20 mg in vial (as hydrochloride) powder for injection ; 2 mg per mL in vial (as hydrochloride) ; 5 mg per mL in vial (as hydrochloride)		
EML status history	First added in 1999 ( <a href="#">TRS 895</a> ) Changed in 2002 ( <a href="#">TRS 914</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2015 ( <a href="#">TRS 994</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Tags	<a href="#">Cancer</a>		
Wikipedia	<a href="#">Daunorubicin</a> 		
DrugBank	<a href="#">Daunorubicin</a> 		

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of additional formulations of daunorubicin (injection 2 mg/mL and 5 mg/mL in vial and powder for injection 20 mg in vial) to the EML and EMLc.

[Expert Committee report !\[\]\(e3f8612927870f2e0f9f5989e6dd3064\_img.jpg\)](#)
